Back to News
Market Impact: 0.35
Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation
Source: PR Newswire
Healthcare & Biotech
Preliminary antitumor responses were observed in 6 of 8 evaluable urothelial carcinoma patients (75%), including patients previously treated with enfortumab vedotin and pembrolizumab. Early activity was also reported in squamous NSCLC, SCLC and prostate cancer; the excerpt provides no further trial details or response rates for those cancers.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
More News
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Linde delivers a good quarter and puts in a fix for an overhang on the stock
- Berkshire Hathaway sells $69.03 million of DaVita (NYSE:DVA) stock
- Stryker plunges 12% Q3 results, guidance disappoint